PriceTargets.com logo

Zymeworks - ZYME Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $37.89
  • Forecasted Upside: 60.27%
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 2 Strong Buy Ratings
$23.64 As of 03/17/2026 01:36 PM ET
▲ +0.021 (0.09%)

This chart shows the closing price for ZYME by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zymeworks Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZYME and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZYME

Analyst Price Target is $37.89
▲ +60.27% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Zymeworks in the last 3 months. The average price target is $37.89, with a high forecast of $58.00 and a low forecast of $22.00. The average price target represents a 60.27% upside from the last price of $23.64.

This chart shows the closing price for ZYME for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 13 contributing investment analysts is to moderate buy stock in Zymeworks. This rating has held steady since April 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/19/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/17/2025
  • 1 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/16/2025
  • 2 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/14/2026
  • 2 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/16/2026

Latest Recommendations

  • 2 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/6/2026HC WainwrightBoost TargetBuy ➝ Buy$32.00 ➝ $46.00
3/3/2026Stifel NicolausBoost TargetBuy ➝ Buy$40.00 ➝ $47.00
3/3/2026Leerink PartnersBoost TargetOutperform ➝ Outperform$52.00 ➝ $58.00
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/17/2025Truist FinancialUpgradeStrong-Buy
12/17/2025Truist FinancialInitiated CoverageBuy$40.00
12/12/2025Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$25.00 ➝ $33.00
12/12/2025Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$33.00
12/3/2025Citizens JmpSet Target$32.00
12/3/2025CitigroupInitiated CoverageBuy ➝ Outperform
12/3/2025Citizens JmpUpgradeStrong-Buy
12/3/2025Citizens JmpInitiated CoverageMarket Outperform$32.00
11/26/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
11/21/2025B. Riley FinancialReiterated RatingBuy ➝ Buy$30.00 ➝ $40.00
11/19/2025Wells Fargo & CompanyBoost TargetCautious ➝ Cautious$17.00 ➝ $25.00
11/19/2025Stifel NicolausBoost TargetBuy ➝ Buy$30.00 ➝ $40.00
11/18/2025HC WainwrightBoost TargetBuy ➝ Buy$26.00 ➝ $32.00
11/17/2025Leerink PartnersSet Target$37.00
11/7/2025Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$15.00 ➝ $17.00
10/28/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
10/27/2025HC WainwrightReiterated RatingBuy ➝ Buy
10/24/2025Wells Fargo & CompanyUpgradeHold
10/24/2025Wells Fargo & CompanyInitiated CoverageEqual Weight ➝ Equal Weight$14.00 ➝ $15.00
10/16/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$20.00 ➝ $23.00
10/14/2025HC WainwrightSet TargetNeutral ➝ Buy$13.00 ➝ $26.00
10/14/2025HC WainwrightUpgradeHold ➝ Strong-Buy
10/10/2025B. Riley FinancialInitiated CoverageBuy$30.00
10/9/2025B. Riley FinancialUpgradeStrong-Buy
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/11/2025CitigroupBoost TargetBuy ➝ Buy$19.00 ➝ $22.00
7/3/2025HC WainwrightReiterated RatingNeutral ➝ Neutral$13.00
5/20/2025TD SecuritiesInitiated CoverageBuy
5/20/2025TD CowenInitiated CoverageBuy
3/11/2025Lifesci CapitalInitiated CoverageOutperform$30.00
3/10/2025HC WainwrightBoost TargetNeutral ➝ Neutral$12.00 ➝ $13.00
3/7/2025CitigroupBoost TargetBuy ➝ Buy$18.00 ➝ $19.00
12/19/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$12.00 ➝ $14.00
12/16/2024JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$18.00
11/22/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$12.00 ➝ $12.00
11/7/2024Leerink PartnersUpgradeMarket Perform ➝ Outperform$10.00 ➝ $25.00
11/4/2024CitigroupBoost TargetBuy ➝ Buy$16.00 ➝ $18.00
11/1/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$12.00 ➝ $12.00
11/1/2024Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$12.00 ➝ $12.00
10/28/2024Stifel NicolausBoost TargetBuy ➝ Buy$21.00 ➝ $28.00
10/22/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$12.00 ➝ $12.00
9/25/2024HC WainwrightBoost TargetNeutral ➝ Neutral$10.00 ➝ $12.00
9/18/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.00
8/2/2024Stifel NicolausBoost TargetBuy ➝ Buy$20.00 ➝ $21.00
6/6/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.00
5/7/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$10.00
5/3/2024CitigroupLower TargetBuy ➝ Buy$17.00 ➝ $16.00
5/3/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$14.00 ➝ $12.00
8/15/2023HC WainwrightReiterated RatingNeutral ➝ Neutral$8.00
5/18/2023CitigroupBoost Target$17.00 ➝ $18.00
5/9/2023Stifel NicolausBoost Target$18.00 ➝ $19.00
3/31/2023JPMorgan Chase & Co.Boost TargetNeutral$8.00 ➝ $9.00
3/21/2023Wells Fargo & CompanyReiterated RatingOverweight$12.00
3/21/2023HC WainwrightReiterated RatingNeutral$8.00
3/10/2023CitigroupLower Target$21.00 ➝ $17.00
3/8/2023GuggenheimReiterated RatingBuy$16.00
1/24/2023HC WainwrightReiterated RatingNeutral$8.00
1/20/2023Leerink PartnersBoost TargetMarket Perform$8.00 ➝ $10.00
1/19/2023GuggenheimBoost Target$15.00 ➝ $16.00
1/4/2023HC WainwrightLower TargetNeutral$10.00 ➝ $8.00
12/22/2022BarclaysBoost TargetEqual Weight$7.00 ➝ $9.00
12/19/2022Jefferies Financial GroupUpgradeHold ➝ Buy$7.70 ➝ $11.00
11/21/2022HC WainwrightBoost TargetNeutral$8.00 ➝ $10.00
11/1/2022HC WainwrightDowngradeBuy ➝ Neutral$40.00 ➝ $8.00
10/24/2022Stifel NicolausLower TargetBuy$21.00 ➝ $18.00
10/21/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$19.00 ➝ $8.00
10/4/2022Wells Fargo & CompanyLower TargetOverweight$45.00 ➝ $9.00
9/14/2022CitigroupLower Target$27.00 ➝ $21.00
8/29/2022CitigroupLower TargetBuy$28.00 ➝ $27.00
5/27/2022Leerink PartnersBoost TargetOutperform$18.00 ➝ $19.00
5/23/2022HC WainwrightLower TargetBuy$44.00 ➝ $40.00
5/5/2022GuggenheimUpgradeNeutral ➝ Buy$14.00
3/15/2022EvercoreInitiated CoverageOutperform$15.00
2/28/2022CitigroupLower Target$53.00 ➝ $30.00
2/9/2022Wells Fargo & CompanyLower TargetOverweight$56.00 ➝ $48.00
2/1/2022Raymond James FinancialLower TargetOutperform$50.00 ➝ $27.00
1/20/2022Raymond James FinancialLower TargetOutperform$74.00 ➝ $62.00
1/6/2022Raymond James FinancialReiterated RatingOutperform$74.00
12/10/2021Leerink PartnersUpgradeMarket Perform ➝ Outperform
12/9/2021Raymond James FinancialDowngradeStrong-Buy ➝ Outperform$74.00
11/15/2021Leerink PartnersReiterated RatingHold$43.00
11/10/2021Leerink PartnersLower TargetMarket Perform$28.00 ➝ $27.00
11/4/2021Raymond James FinancialSet TargetStrong-Buy$74.00
11/4/2021Leerink PartnersLower TargetMarket Perform$43.00 ➝ $28.00
10/6/2021Jefferies Financial GroupInitiated CoverageHold$32.00
9/30/2021Wells Fargo & CompanyReiterated RatingBuy$56.00
9/20/2021HC WainwrightReiterated RatingBuy$44.00
9/13/2021Raymond James FinancialSet TargetStrong-Buy$74.00
8/6/2021Raymond James FinancialReiterated RatingStrong-Buy$74.00
8/5/2021HC WainwrightLower TargetBuy$55.00 ➝ $44.00
5/7/2021HC WainwrightLower TargetBuy$57.00 ➝ $55.00
5/6/2021Raymond James FinancialSet TargetStrong-Buy$74.00
3/30/2021Credit Suisse GroupInitiated CoverageOutperform$55.00
(Data available from 3/17/2021 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2025
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/18/2025
  • 2 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2025
  • 3 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2025
  • 5 very positive mentions
  • 22 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
12/17/2025
  • 5 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/16/2026
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/15/2026
  • 6 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/17/2026

Current Sentiment

  • 6 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Zymeworks logo
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $23.64
Low: $23.48
High: $23.93

50 Day Range

MA: $23.45
Low: $22.02
High: $25.46

52 Week Range

Now: $23.64
Low: $9.03
High: $28.49

Volume

160,480 shs

Average Volume

793,986 shs

Market Capitalization

$1.74 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Zymeworks?

The following Wall Street sell-side analysts have issued stock ratings on Zymeworks in the last twelve months: B. Riley Financial, Inc., Citigroup Inc., Citizens Jmp, HC Wainwright, JPMorgan Chase & Co., Leerink Partners, Stifel Nicolaus, TD Cowen, TD Securities, Truist Financial Corporation, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for ZYME.

What is the current price target for Zymeworks?

0 Wall Street analysts have set twelve-month price targets for Zymeworks in the last year. Their average twelve-month price target is $37.89, suggesting a possible upside of 60.4%. Leerink Partners has the highest price target set, predicting ZYME will reach $58.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $22.00 for Zymeworks in the next year.
View the latest price targets for ZYME.

What is the current consensus analyst rating for Zymeworks?

Zymeworks currently has 1 sell rating, 1 hold rating, 9 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ZYME.

What other companies compete with Zymeworks?

Other companies that are similar to Zymeworks include Arcellx, Belite Bio, Kymera Therapeutics, Rhythm Pharmaceuticals and Protagonist Therapeutics. Learn More about companies similar to Zymeworks.

How do I contact Zymeworks' investor relations team?

Zymeworks' physical mailing address is 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709. The company's listed phone number is (302) 274-8744 and its investor relations email address is [email protected]. The official website for Zymeworks is zymeworks.com. Learn More about contacing Zymeworks investor relations.